Harvard Women's Health Watch

Negotiating the "bio-identicals" controversy

The FDA has taken issue with certain pharmacies that produce custom-compounded hormone therapy products, because some of them claim, without proof, that their products are safer or more effective than traditionally-produced hormones.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In